stents

Escándalo con los resultados del EXCEL que hicieron “caer” las últimas guías

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might limit the applicability of older randomized trials to contemporary clinical practice. In this case, we look at patients and devices used in the contemporary clinical practice vs. those in the EXTEND DAPT. These differences were associated with attenuated<a href="https://solaci.org/en/2022/01/25/clnical-practice-dissociated-from-study-outcomes-bad-news-for-our-patients/" title="Read more" >...</a>

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most Relevant<a href="https://solaci.org/en/2022/01/10/the-most-relevant-articles-of-2021-in-pharmacology/" title="Read more" >...</a>

The Most Relevant of 2021 In Coronary Disease

This last year, new data in coronary disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence.&nbsp; In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The Most<a href="https://solaci.org/en/2022/01/06/the-most-relevant-of-2021-in-coronary-disease/" title="Read more" >...</a>

The Most Read Articles of 2021: Pharmacology

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, pharmacology. Follow us to keep up to date. The Most Read Articles of 2021: Pharmacology 01- Swan Ganz Associated with Better Outcomes in Cardiogenic Shock: Is It Back? The&nbsp;Swan<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-pharmacology/" title="Read more" >...</a>

The Most Read Articles of 2021: Coronary Disease

A new year is coming to an end and at SOLACI we are going over the most read studies on our website, on a vital topic, peripheral vascular disease. Follow us to keep up to date. Most Read Articles on Coronary Disease 01- Post MI Betablockers for Good? Patients receiving optimal medical treatment after MI<a href="https://solaci.org/en/2021/12/24/the-most-read-articles-of-2021-coronary-disease/" title="Read more" >...</a>

AHA 2021 | Meta-análisis de cirugía vs angioplastia para el tronco de la coronaria izquierda

AHA 2021 | Meta-Analysis of Surgery vs. Angioplasty in Left Main Coronary Artery Disease

According to this new meta-analysis (presented at AHA&nbsp;2021 and published in The Lancet), mortality is similar between surgery and angioplasty to treat left main coronary artery in patients with simple or intermediate anatomy. This new study estimates that, after 5&nbsp;years, mortality with surgery would be 11.2% vs. 10.2% with angioplasty, a non-significant difference. This debate<a href="https://solaci.org/en/2021/11/25/aha-2021-meta-analysis-of-surgery-vs-angioplasty-in-left-main-coronary-artery-disease/" title="Read more" >...</a>

Sugar-trial-tct2021

TCT 2021 | SUGAR Trial: Polymer-Free Stent in Diabetes

In CAD patients with diabetes the polymer-free amphilimus-eluting stent resulted non-inferior to the polymer-based zotarolimus-eluting Resolute Onyx. This new device, in addition to ultrathin struts, has already been found non-inferior to the Resolute Integrity in the general population at 3-year followup. Researchers believe that the new amphiphilic carrier might be especially useful in diabetic patients<a href="https://solaci.org/en/2021/11/09/tct-2021-sugar-trial-polymer-free-stent-in-diabetes/" title="Read more" >...</a>

The Most Read Articles in Interventional Cardiology of October

The Most Read Articles in Interventional Cardiology in October

01- ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality The&nbsp;ISCHEMIA&nbsp;study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Read also HERE 02- Chile Sessions 2021 | Clinical Case Contest for Young Interventionists It is with great<a href="https://solaci.org/en/2021/11/05/the-most-read-articles-in-interventional-cardiology-in-october/" title="Read more" >...</a>

10 Years Treating Bifurcations: Have We Made Progress?

Bifurcations have been, are and will be challenging. However, we have to admit we have gained experience and have more tools than pioneer interventionists and many of the early experts who have made history.&nbsp; This study assessed the ten-year trends in coronary bifurcation percutaneous coronary intervention (PCI) looking at patient and lesion characteristics, devices used,<a href="https://solaci.org/en/2021/10/26/10-years-treating-bifurcations-have-we-made-progress/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug-Eluting Balloons Find Their Niche

According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>

Top